BERLIN and HEIDELBERG, Germany, February 14 /PRNewswire/ -- ProBioGen, the international cell specialists from Berlin, and Heidelberg based Affimed Therapeutics AG, specializing in the development of recombinant antibodies for the treatment of cancer, announce the execution of a development collaboration. Within the frame of this contract, ProBioGen will develop a high-producing cell-line as well as a production process and procedure with GMP-manufacturing for clinical material for a TandAB, a bi-specific, tetravalent recombinant antibody, from Affimed.
Meanwhile, both companies are discussing extending their collaboration to other products. The co-operation between ProBioGen and Affimed reached a new level of intensity with this contract. “We are very happy to use our expression technology for a key product for Affimed”, said Michael Schlenk, CEO of ProBioGen. “It has already become obvious during our negotiations that the cultures of our enterprises fit very well together.”
“ProBioGen’s high competence and professional project management really convinced us. The collaboration has been very constructive from the beginning based on a highly efficient exchange of information and is already showing first promising results. Thus, we are looking forward to extending our collaboration expecting significant benefits for the development of our products,” said Dr. Rolf H. Gunther, CEO of Affimed.
ProBioGen Contact Affimed Contact Dirk Halemba Dr. Florian Fischer Goethestrasse 54 Im Neuenheimer Feld 582 13068 Berlin D-69120 Heidelberg Tel.: +49-(30)-92400613 +49-(0)-6221-65307-0 Fax: +49-(30)-92400619 +49-(0)-6221-65307-77 e-mail: dirk.halemba@probiogen.de e-mail: f.fischer@affimed.com
ProBioGen AG
CONTACT: ProBioGen Contact: Dirk Halemba, Goethestrasse 54, 13068 Berlin,Tel.: +49-(30)-92400613, Fax: +49-(30)-92400619, e-mail:dirk.halemba@probiogen.de; Affimed Contact, Dr. Florian Fischer, ImNeuenheimer Feld 582, D-69120 Heidelberg, +49-(0)-6221-65307-0,+49-(0)-6221-65307-77, e-mail: f.fischer@affimed.com
